Researchers produce effective anthrax vaccine from tobacco

The new production method aims to also could help the government and health care providers worldwide deal with supply shortages, as one acre of plants can produce 360 million doses in a year.

The research community are hailing this research as a breakthrough in finding a safe and effective method of producing large quantities of vaccine for anthrax, one of the top bioterrorism threats facing the US.

The study, conducted by scientists at the National Institutes of Health (NIH) in collaboration with the University of Central Florida (UCF), involved immunising mice with a vaccine produced in UCF professor Henry Daniell's laboratory through the genetic engineering of tobacco plants.

The mice survived lethal doses of anthrax administered later by National Institutes of Health researchers.

Daniell and his colleagues injected the vaccine gene into the chloroplast genome of tobacco cells, partly because those plants grow much faster than carrots, tomatoes and coffee.

They grew the cells for several weeks in Daniell's laboratory. Tests showed the vaccine taken from the plants was just as potent as the one produced through fermentation but lacks the bacterial toxin that can cause harmful side effects.

Researchers then injected the vaccine into mice to immunise them against anthrax and sent the mice to NIH labs, where they survived doses of anthrax several times stronger than the amounts to which humans have been exposed.

The next step for the anthrax vaccine would involve a company working with NIH to conduct clinical trials.

Human subjects would be injected only with the vaccine and not with anthrax itself, and scientists would then check the subjects' immunity levels. The vaccine later could be mass-produced and stockpiled for emergencies.

"Anthrax vaccine is very much in need, primarily because of bioterrorism concerns," but in the US, only one company has the capacity to produce the vaccine, and it is made in very small quantities by fermentation,"​ Daniell said.

"We can provide enough doses of a safe and effective vaccine for all Americans from just one acre of tobacco plants,"​ he added.

Current production of the vaccine involves an expensive fermentation process that can cause harmful side effects such as inflammation, flu-like symptoms and rashes. This has prompted some people to refuse to be vaccinated.

Daniell conducted his study with part of a $1 million (€842,000) NIH grant and a $2 million US Department of Agriculture grant that cover research related to genetic engineering in plants as a way to produce therapies for several diseases.

His work holds promise for treating other diseases, including diabetes and hepatitis, and improving vaccines for plague, cholera and other bioterrorism agents.

Daniell is developing a new technology that would enable vaccines to be administered orally and allow effective and less expensive treatments to be more accessible worldwide.

Fruits and vegetables such as carrots and tomatoes hold promise as a way for people to take anthrax vaccines orally in capsules of dried plant cells that contain correct doses of the protective antigen.

If that research is successful, the needs for requiring doctors to administer the shots and for shipping vaccines in refrigerated trucks, both of which can be especially difficult in poorer nations, would be eliminated.

According to the Pentagon, the military now administers the vaccine with three shots in the first four weeks, three more in the next 17 months and then annual booster shots.

The results of the NIH-funded study are featured in the December issue of the Infection & Immunity​ journal.